{
  "nctId": "NCT03795610",
  "briefTitle": "IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma",
  "officialTitle": "Phase 2 Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma",
  "protocolDocument": {
    "nctId": "NCT03795610",
    "filename": "Prot_SAP_002.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2021-12-03",
    "uploadDate": "2025-07-03T17:09",
    "size": 992758,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03795610/document/Prot_SAP_002.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 16,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2020-03-06",
    "completionDate": "2023-08-24",
    "primaryCompletionDate": "2022-12-22",
    "firstSubmitDate": "2018-12-21",
    "firstPostDate": "2019-01-08"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Have locally advanced that is amenable to surgical resection\n* Must be able to swallow tablets\n* Must be able to undergo a core tumor biopsy.\n* Must have adequate organ function.\n\nExclusion Criteria:\n\n* Diagnosis of cutaneous squamous cell carcinoma (SCC) or Epstein-Barr virus (EBV) related nasopharynx cancer.\n* Planned major surgery within 4 weeks prior to initiation of study drug\n* Patients treated with chemotherapy, biologic therapy, or other investigational agent within \\< 28 days of starting study drug\n* History of infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C virus (HCV)\n* On going treatment with chronic immunosuppressants (e.g., cyclosporine) or systemic steroids\n* Prior surgery or gastrointestinal dysfunction that may affect drug absorption (e.g. gastric bypass surgery, gastrectomy)\n* Female subjects who are pregnant or breastfeeding\n* Concurrent active malignancy other than nonmelanoma skin cancer, carcinoma in situ of the cervix, or prostate intraepithelial neoplasia",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Participants Experiencing Adverse Events",
        "description": "To determine safety and tolerability of IPI-549 in patients with locally advanced HNSCC.",
        "timeFrame": "7 weeks"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 1
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 14,
    "complexityCategory": "Simple"
  },
  "collectionDate": "2025-09-22T02:30:45.927Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}